Latest Studies & News Bulletins
NATIONAL INSTITUTES OF HEALTH

News Release: Tuesday, July 9, 2002
NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit
JAMA Study:
Hormone Replacement Therapy in Relation to Breast Cancer Increased by 60% to 85% in recent long-term users of HRT

 U.S. Food and Drug Administration of Center for Drug Evaluation and Research

FDA Statement on the Results of the Women's Health Initiative (8/13/2002) Women's Health Initiative (WHI) Results.
Signal Need for Reassessment of Risks and Benefits of Conjugated Equine Estrogens/medroxyprogesterone Acetate (Prempro) in Postmenopausal Women.
 FDA Approves New Labeling and Provides
New Advice to:
Postmenopausal Women

Who Use or Who Are Considering Using Estrogen and Estrogen With Progestin